Advances in Our Understanding of the Interaction of Drugs with T-cells: Implications for the Discovery of Biomarkers in Severe Cutaneous Drug Reactions
Por:
Hernandez-Jaimes O.A., Cazares-Olvera D.V., Line J., Moreno-Eutimio M.A., Gómez-Castro C.Z., Naisbitt D.J., Castrejón-Flores J.L.
Publicada:
1 ene 2022
Resumen:
Drugs can activate different cells of the immune system and initiate an immune response that can lead to life-threatening diseases collectively known as severe cutaneous adverse reactions (SCARs). Antibiotics, anticonvulsants, and antiretrovirals are involved in the development of SCARs by the activation of aß naïve T-cells. However, other subsets of lymphocytes known as nonconventional T-cells with a limited T-cell receptor repertoire and innate and adaptative functions also recognize drugs and drug-like molecules, but their role in the pathogenesis of SCARs has only just begun to be explored. Despite 30 years of advances in our understanding of the mechanisms in which drugs interact with T-cells and the pathways for tissue injury seen during T-cell activation, at present, the development of useful clinical biomarkers for SCARs or predictive preclinical in vitro assays that could identify immunogenic moieties during drug discovery is an unmet goal. Therefore, the present review focuses on (i) advances in the understanding of the pathogenesis of SCARs reactions, (ii) a description of the interaction of drugs with conventional and nonconventional T-cells, and (iii) the current state of soluble blood circulating biomarker candidates for SCARs.
Filiaciones:
Hernandez-Jaimes O.A.:
Instituto Politécnico Nacional, Unidad Profesional Interdisciplinaria de BiotecnologíaMéxico City 07340, Mexico
Cazares-Olvera D.V.:
Instituto Politécnico Nacional, Unidad Profesional Interdisciplinaria de BiotecnologíaMéxico City 07340, Mexico
Line J.:
MRC Centre for Drug Safety Science, Department of Pharmacology, University of Liverpool, Liverpool, L69 3GE, United Kingdom
Moreno-Eutimio M.A.:
Facultad de Química, Universidad Nacional Autónoma de MéxicoMéxico City 04510, Mexico
Gómez-Castro C.Z.:
Investigador CONACYT. Universidad Autónoma del Estado de HidalgoHidalgo CP 42184, Mexico
Naisbitt D.J.:
MRC Centre for Drug Safety Science, Department of Pharmacology, University of Liverpool, Liverpool, L69 3GE, United Kingdom
Castrejón-Flores J.L.:
Instituto Politécnico Nacional, Unidad Profesional Interdisciplinaria de BiotecnologíaMéxico City 07340, Mexico
|